Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune-mediated inflammatory diseases: A European retrospective observational study.
Laurent GoessensJean-Frédéric ColombelAn OuttierMarc FerranteJoao SabinoCiaran JudgeReza SaeidiLouise RabbittAlessandro ArmuzziEugeni DomènechGeorge MichalopoulosAnneline CremerFrancisco Javier García-AlonsoTamas MolnarKonstantinos KarmirisKrisztina GecseJoep Van OostromMark LöwenbergKlaudia FarkasRaja AtreyaDavide Giuseppe RibaldoneChristian Philipp SelingerFrank HoentjenBenoit BihinShaji Sebastiannull nullJean-François RahierPublished in: United European gastroenterology journal (2021)
Combination of biologics and small molecules in patients with IBD and IMID/EIM seems to be a promising therapeutic strategy but is also associated with a risk of opportunistic infections or infections leading to hospitalisation in 10%.
Keyphrases